Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Innate Pharma S.A.NASDAQ: IPHA

Weighted Avg Shares (Diluted) · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares (diluted) grows 12.8% year over year

Q4 FY2025 weighted avg shares (diluted) of 91.41M shares rose 12.8% year over year. Over 3 fiscal years it compounded at +3.9% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
91.41M— QoQ
Last fiscal yearDec 2025
89.42M+10.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%——
1 year+10.3%——
3-year CAGR+3.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
89.42M EUR
Year-over-year change
+10.3%
4-year CAGR
+3.0%

Weighted Avg Shares (Diluted) vs competitors

How IPHA compares with its peers on the latest reported figures

  • IPHA's FY2025 weighted avg shares (diluted) of 89.42M shares is the 3rd highest of the 9 companies compared; the peer median is 52.29M shares.
  • Its year-over-year change of +10.3% is the 7th highest of 9, against a peer median of +31.5%.
  • Over three fiscal years its annual growth of +3.9% compares with a peer median of +22.7%.
IPHA Competitors Peer median
Weighted Avg Shares (Diluted) for IPHA and competitors
Company Period LTM YoY 3-year CAGR
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+3.9%
NVCTNuvectis Pharma, Inc.LTM Mar 202622.33M +21.4%+19.9%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding IPHA) 52.29M+31.5%+22.7%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.